Lactobacillus acidophilus – LA02 (DSM 21717)

Tabella dei contenuti

Clinical indications

kidney stones, rebalance of intestinal microbiota, vaginal candidiasis, Vaginal health

Area of use

Gastroenterology strain | Gut permeability, anti-inflammatory activity

Characteristics

FUNCTIONALITY
Rebalance of intestinal microbiota

Scientific support

In vitro study
Del Piano M. et al. In Vitro Sensitivity of Probiotics to Human Pancreatic Juice. J. Clin. Gastroenterol. Vol 42, Suppl. 3, Part 2, Sept. 2008. (LA02, LPC00).

Internal data in vitro on gut permeability protection and anti-inflammatory activity available upon request for LA02.


Gastroenterology blend | IBS

  • Lactobacillus plantarum – LP01 (LMG P-21021)
  • Lactobacillus acidophilus – LA02 (DSM 21717)

Characteristics

DAILY DOSAGE IN CLINICAL STUDY
5 billion CFU + 5 billion CFU


FUNCTIONALITY
IBS • Reduction of gastro-intestinal discomfort • Reduction of inflammation

Scientific support

Human clinical trial
Saggioro A. Probiotics in the treatment of Irritable Bowel Syndrome. J Clin Gastroenterol, 2004; 38(8): S104-106.

In vitro study
Nicola S. et al. Immunomodulation properties of Lactobacillus plantarum LP01 (LMG P-21021) and Lactobacillus acidophilus LA02 (DSM 21717) blend.

Internal data in vitro on gut permeability and anti-inflammatory activity available upon request.


Gynecology blend | Vaginal candidiasis

  • Lactobacillus acidophilus – LA02 (DSM 21717)
  • Lactobacillus fermentum – LF10 (DSM 19187)

Characteristics

DAILY DOSAGE IN CLINICAL STUDY
1,2) 400 million CFU/strain/tablet + Carbon dioxide + FOS + Arabinogalactan


FUNCTIONALITY
Vaginal health • Inhibition of Candida strains • Innovative effervescent slow release tablet for enhanced delivery and activity of lactobacilli • Counteraction of Candida vulvovaginitis

Scientific support

Human clinical trials
1) Vicariotto F. et al. Effectiveness of the association of 2 probiotic strains formulated in a slow release vaginal product, in women affected by vulvovaginal candidiasis: a pilot study. J Clin Gastroenterol. 2012; 46 Suppl:S73-80.
2) Murina F. et al. Can Lactobacillus fermentum LF10 and Lactobacillus acidophilus LA02 in a Slow-release Vaginal Product be Useful for Prevention of Recurrent Vulvovaginal Candidiasis? J Clin Gastroenterol. 2014; 48:S102-105.

In vitro study
Deidda F. et al. The In Vitro Effectiveness of Lactobacillus fermentum Against Different Candida Species Compared With Broadly Used Azoles. J Clin Gastroenterol. 2016; 50:S171-S174.


Urology strain | Kidney stones

Characteristics

FUNCTIONALITY
Oxalate degradation • Reduction of intestinal inflammation • Potential reduction of kidney stones incidence

Scientific support

In vitro studies
Mogna L. et al. Screening of different probiotic strains for their in vitro ability to metabolise oxalates: any prospective use in humans? (LPC09, LA02, LP01, LRE02, BR03, BL03) J Clin Gastroenterol. 2014; 48 Suppl:S91-95.

+ Internal data on anti-inflammatory and anti-oxidant properties available upon request on certain strains


Gut-brain strain | Parkinson’s disease

Scientific support

Luca Magistrelli et al. Probiotics May Have Beneficial Effects in Parkinson’s Disease: In vitro Evidence. Front. Immunol., 07 May 2019